- All sections
- C - Chemistry; metallurgy
- C07K - Peptides
- C07K 14/725 - T-cell receptors
Patent holdings for IPC class C07K 14/725
Total number of patents in this class: 6819
10-year publication summary
|
118
|
303
|
397
|
507
|
709
|
823
|
1003
|
1170
|
920
|
236
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1144 |
549 |
| The Trustees of the University of Pennsylvania | 4122 |
207 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
205 |
| Autolus Limited | 232 |
124 |
| Memorial Sloan-Kettering Cancer Center | 1789 |
121 |
| The Regents of the University of California | 18943 |
117 |
| Novartis AG | 11238 |
102 |
| Juno Therapeutics, Inc. | 365 |
97 |
| Board of Regents, The University of Texas System | 5370 |
92 |
| CRISPR Therapeutics AG | 361 |
87 |
| Cellectis | 397 |
80 |
| City of Hope | 943 |
75 |
| Adaptimmune Limited | 179 |
70 |
| Kite Pharma, Inc. | 315 |
68 |
| Immunocore Limited | 190 |
67 |
| Lentigen Technology, Inc. | 91 |
67 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
63 |
| Fred Hutchinson Cancer Center | 376 |
57 |
| Xlifesc, Ltd. | 55 |
51 |
| The Board of Trustees of the Leland Stanford Junior University | 6054 |
48 |
| Other owners | 4472 |